title: [Tirofiban improved the prognosis of senior acute coronary syndrome patients received percutaneous coronary intervention].
abstract: OBJECTIVE
  To examine if tirofiban may improve the prognosis in aged acute coronary syndrome (ACS) patients received percutaneous coronary intervention (PCI).
  
  
  METHODS
  Three hundred and twenty-five ACS patients (age ≥ 60 years), all received drug-eluting stents implantation, were assigned into tirofiban group (n = 210) to receive tirofiban+aspirin and clopidogrel and control group (n = 115) to received aspirin and clopidogrel only. The incidence of thrombolysis in myocardial infarction (TIMI) grade 3 after PCI, in-stent thrombosis, slight/severe bleeding, platelet decrease, myocardial infarction (MI) and target vessel revascularization (TVR) within 30 days and 12 months after PCI and 30 days and 12 months mortality post PCI.
  
  
  RESULTS
  In comparison with the control group, the tirofiban group had significantly higher TIMI grade 3 flow after PCI (99.05% vs. 94.78%, P < 0.05), lower in-stent thrombosis (0.47% vs. 2.61%, P < 0.05), as well as lower mortality, MI, and TVR in 30 days and 12 months after PCI (30 days: 0, 0.47% and 0.47% vs. 2.61%, 3.48% and 2.61%; 12 months: 0, 0.47% and 0.47% vs. 2.61%, 5.22% and 5.22%, P < 0.05 or P < 0.01). No significant difference was found (both P > 0.05) in slight bleeding (7.14% vs. 4.35%) and severe bleeding (0 vs. 0) between tirofiban group and control group. A slight difference in thrombocytopenia was found between tirofiban group and control group (0.95% vs. 0), but it failed to reach the level of statistical significance (P > 0.05).
  
  
  CONCLUSIONS
  Tirofiban may improve the TIMI grade flow in senior ACS patients after PCI. It also decreases the incidence of in-stent thrombosis, mortality, MI, and TVR in 30 days and 12 months after PCI, without causing increase in severe bleeding and platelet penia. Therefore, it may improve the short/long-term prognosis for these patients.
authors.affiliation: The Institute of Geriatric Cardiology, the General Hospital of Chinese PLA, Beijing, China.
authors.forename: Yu-xiao
authors.initials: YX
authors.lastname: Zhang
authors.forename: Cai-yi
authors.initials: CY
authors.lastname: Lu
authors.forename: Sheng-hua
authors.initials: SH
authors.lastname: Zhou
authors.forename: Qiao
authors.initials: Q
authors.lastname: Xue
authors.forename: Lei
authors.initials: L
authors.lastname: Gao
authors.forename: Jin-wen
authors.initials: JW
authors.lastname: Tian
authors.forename: Wei
authors.initials: W
authors.lastname: Gao
authors.forename: Rui
authors.initials: R
authors.lastname: Chen
authors.forename: Jin-Yue
authors.initials: JY
authors.lastname: Zhai
authors.forename: Li-Jun
authors.initials: LJ
authors.lastname: Li
mesh_terms: D054058:Acute Coronary Syndrome / Q000628:therapy*; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D001241:Aspirin / Q000627:therapeutic use; D000077144:Clopidogrel; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011379:Prognosis; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077466:Tirofiban; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D010975:Platelet Aggregation Inhibitors; D014443:Tyrosine; D000077144:Clopidogrel; D000077466:Tirofiban; D013988:Ticlopidine; D001241:Aspirin